How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
9
VVOS Quote, Financials, Valuation and Earnings
Last price:
$1.60
Seasonality move
:
-37.89%
Day range:
$1.66 - $1.80
52-week range:
$1.66 - $7.95
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.85x
P/B ratio:
6.07x
Volume:
128.5K
Avg. volume:
138.4K
1-year change:
-58.5%
Market cap:
$15.4M
Revenue:
$15M
EPS (TTM):
-$1.97
Analysts' Opinion
-
Consensus RatingVivos Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.00, Vivos Therapeutics, Inc. has an estimated upside of 192.4% from its current price of $1.71.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.50 representing 100% downside risk from its current price of $1.71.
Fair Value
-
According to the consensus of 3 analysts, Vivos Therapeutics, Inc. has 192.4% upside to fair value with a price target of $5.00 per share.
VVOS vs. S&P 500
-
Over the past 5 trading days, Vivos Therapeutics, Inc. has underperformed the S&P 500 by -7.39% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Vivos Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Vivos Therapeutics, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Vivos Therapeutics, Inc. reported revenues of $6.8M.
Earnings Growth
-
Vivos Therapeutics, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Vivos Therapeutics, Inc. reported earnings per share of -$0.49.
Enterprise value:
24.8M
EV / Invested capital:
--
Price / LTM sales:
0.85x
EV / EBIT:
--
EV / Revenue:
1.43x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.61x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$8.6M
Return On Assets:
-91.38%
Net Income Margin (TTM):
-98.77%
Return On Equity:
-315.1%
Return On Invested Capital:
-153.33%
Operating Margin:
-69.79%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $14.5M | $14.6M | $17.3M | $3.9M | $6.8M | |
| Gross Profit | $8.1M | $8.3M | $8.6M | $2.2M | $3.6M | |
| Operating Income | -$19.1M | -$12.7M | -$16.3M | -$2.6M | -$4.7M | |
| EBITDA | -$18.4M | -$12.1M | -$15.3M | -$2.5M | -$4.4M | |
| Diluted EPS | -$14.70 | -$4.95 | -$1.97 | -$0.40 | -$0.49 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $34M | $9.7M | $2M | $7.4M | $5.8M | |
| Total Assets | $41M | $18.4M | $10.3M | $15.3M | $25.6M | |
| Current Liabilities | $8.2M | $6M | $7.2M | $5.1M | $7.4M | |
| Total Liabilities | $8.6M | $8.5M | $10.3M | $7.7M | $23.1M | |
| Total Equity | $32.5M | $9.9M | $46K | $7.7M | $2.5M | |
| Total Debt | $1.3M | $2.4M | $1.6M | $1.2M | $11.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$12.2M | -$12.5M | -$14.4M | -$4.2M | -$4.2M | |
| Cash From Investing | -$888K | -$568K | -$6.1M | -$192K | $83K | |
| Cash From Financing | $7.4M | $18.4M | $17.3M | $3.8M | $2.8M | |
| Free Cash Flow | -$13.1M | -$13.1M | -$15.4M | -$4.4M | -$4.1M | |
VVOS
Sector
Market Cap
$15.4M
$25.9M
Price % of 52-Week High
21.51%
51.6%
Dividend Yield
0%
0%
Shareholder Yield
-40.24%
-1.66%
1-Year Price Total Return
-58.5%
-18.99%
Beta (5-Year)
6.895
0.485
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.83
200-day SMA
Sell
Level
$3.11
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$2.02
Relative Strength Index (RSI14)
Sell
Level
35.70
ADX Line
Neutral
Level
0
Williams %R
Buy
Level
-92.6068
50-day SMA
Sell
Level
$2.10
MACD (12, 26)
Buy
Level
0.14
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-8.7079)
Sell
CA Score
(Annual)
Level (-4.7021)
Sell
Beneish M-Score
(Annual)
Level (-0.9667)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (6.8369)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (8)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh, Susan McCullough, RaeAnn Byrnes, Todd Huntsman, and R. Kirk Huntsman on July 7, 2016 and is headquartered in Littleton, CO.
Stock Forecast FAQ
In the current month, VVOS has received 2 Buy ratings 1 Hold ratings, and 0 Sell ratings. The VVOS average analyst price target in the past 3 months is $5.00.
-
Where Will Vivos Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Vivos Therapeutics, Inc. share price will rise to $5.00 per share over the next 12 months.
-
What Do Analysts Say About Vivos Therapeutics, Inc.?
Analysts are divided on their view about Vivos Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Vivos Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $2.50.
-
What Is Vivos Therapeutics, Inc.'s Price Target?
The price target for Vivos Therapeutics, Inc. over the next 1-year time period is forecast to be $5.00 according to 3 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is VVOS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Vivos Therapeutics, Inc. is a Buy. 2 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of VVOS?
You can purchase shares of Vivos Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Vivos Therapeutics, Inc. shares.
-
What Is The Vivos Therapeutics, Inc. Share Price Today?
Vivos Therapeutics, Inc. was last trading at $1.60 per share. This represents the most recent stock quote for Vivos Therapeutics, Inc.. Yesterday, Vivos Therapeutics, Inc. closed at $1.71 per share.
-
How To Buy Vivos Therapeutics, Inc. Stock Online?
In order to purchase Vivos Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get VVOS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
VVOS
Sector
P/E ratio
--
23.82x
PEG ratio
--
-0.01x
P/B ratio
6.07x
1.83x
Price / LTM sales
0.85x
1.56x
Growth Metrics
VVOS
Sector
Revenue growth
75.73%
4.18%
Earnings growth
-24.53%
9.66%
Revenue (5-year growth)
5.7%
6.28%
Earnings forecast
-$0.48
-$0.18
Profitability
VVOS
Sector
Profitability FY 2024
$8.4M
$3.1M
Return on invested capital
-153.33%
-32.89%
Return on assets
-91.38%
-29.56%
Return on equity
-315.1%
-38.66%
Earnings Date
Last Earnings Date
Nov
19
Next Earnings Date
Mar
31
Estimated Next Earnings Date
Feb
18
Balance Sheet
VVOS
Sector
Total cash
$3.1M
$25.2M
Short term investments
--
$25.1M
Total assets
$15.3M
$73M
Long term debt
$11.8M
$3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 65x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
72
BNAI alert for Jan 29
Brand Engagement Network, Inc. [BNAI] is down 16.89% over the past day.
Buy
82
STX alert for Jan 29
Seagate Technology Holdings Plc [STX] is up 0.83% over the past day.
Buy
84
GDXU alert for Jan 29
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 12.19% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
